{"name":"Rempex (a wholly owned subsidiary of Melinta Therapeutics, LLC)","slug":"rempex-a-wholly-owned-subsidiary-of-melinta-therapeutics-llc","ticker":"","exchange":"","domain":"","description":"","hq":"","founded":0,"employees":"","ceo":"","sector":"","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"","metrics":{"revenue":0,"revenueGrowth":0,"grossMargin":0,"rdSpend":0,"netIncome":0,"cash":0,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[{"name":"Infectious Disease","slug":"infectious-disease","revenue":0,"percentOfTotal":0,"drugCount":1,"colorKey":"oncology","drugs":[{"name":"Meropenem-Vaborbactam","genericName":"Meropenem-Vaborbactam","slug":"meropenem-vaborbactam","indication":"Complicated urinary tract infections (cUTI) caused by susceptible gram-negative bacteria","status":"marketed"}]}],"pipeline":[{"name":"Meropenem-Vaborbactam","genericName":"Meropenem-Vaborbactam","slug":"meropenem-vaborbactam","phase":"marketed","mechanism":"Meropenem-vaborbactam is a carbapenem antibiotic combined with a beta-lactamase inhibitor that kills bacteria by inhibiting cell wall synthesis while protecting the carbapenem from enzymatic degradation.","indications":["Complicated urinary tract infections (cUTI) caused by susceptible gram-negative bacteria","Hospital-acquired and ventilator-associated bacterial pneumonia (HABP/VABP) caused by susceptible gram-negative bacteria"],"catalyst":""}],"recentEvents":[],"realNews":[],"patents":[],"drugCount":1,"phaseCounts":{"marketed":1},"enrichmentLevel":0,"visitCount":3,"keyCompetitors":[],"therapeuticFocus":[],"financials":null,"yahoo":null}